Skip to main content
. 2021 Jul 3;59(1):882–890. doi: 10.1080/13880209.2021.1944221

Figure 2.

Figure 2.

LC-MS/MS chromatograms oflaurolitsine and IS nuciferine in different matrix. (A) Blank biological matrix; (B) LLOQ sample of different biological matrix (laurolistine 1 ng/mL−1); (C) rat plasma of 1 h after i.v. administration laurolistine, rat urine of 0–4 h after p.o. administration laurolistine, rat liver tissue of 2 h after p.o. administration laurolistine; (D) rat plasma of 1 h after p.o. administration laurolitsine.